Free Newsletter
Icahn officially puts Biogen under siege
Is Biogen Idec ready for the Icahn onslaught? Activist shareholder and infamous thorn in management's side Carl Icahn made his proxy-fight threats official Friday with a Securities and Exchange Commission filing. Icahn outlined his pitch to take over four board seats, plus fix the size of the board at 13 and move Biogen's state of incorporation to shareholder-friendly state North Dakota.
Icahn has been goosing Biogen management for some 18 months now, ever since he strong-armed the company into putting itself up for sale. Then, after Biogen failed to find a buyer, he mounted a proxy fight to put his own people in three board seats, saying that the company had deliberately sabotaged its own auction process. And now there's this year's model.
Meanwhile, Icahn is stirring up trouble at Amylin, trying to push his five nominees onto that company's board of directors. (Another minority investor is pressing for its own slate of five, too.) He's a busy, busy man.
- read the Wall Street Journal story
Related Articles:
Amid proxy fight, Biogen chief earns $11.3M
Icahn on the prowl for Biogen, too
Icahn makes play for Amylin control
Biogen works to stave off proxy fights
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: